Bronchial Asthma in Children and Status Asthmaticus
1. Osmonova Gulnaz Zh.
2. Amal Azim
3. Hania Najeeb
4. Salahaldin
(1. Teacher, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
2. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
3. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic.
4. Student, International Medical Faculty, Osh State University, Osh, Kyrgyz Republic)
Abstract
Background
Bronchial asthma is the most common chronic respiratory disease of childhood, affecting 339 million people globally with disproportionate burden in low- and middle-income countries. Status asthmaticus, the life-threatening failure of bronchodilator therapy, represents the critical apex of disease severity, requiring intensive care and carrying significant mortality. Updated epidemiological and therapeutic intelligence is essential for clinicians who must navigate the tension between controller adherence, acute exacerbation management, and the prevention of near-fatal events.
Methods
A structured scoping review (January 2019 – December 2024) was undertaken using PubMed, EMBASE, Cochrane, WHO IRIS, and grey literature. Eligible studies described (i) epidemiology, pathophysiology, or clinical features of childhood asthma and status asthmaticus; (ii) diagnostic or therapeutic advances; (iii) intensive care management and outcomes. Global Burden of Disease (GBD) 2023 supplied mortality and disability estimates. Where randomised trials were scarce, high-quality cohort studies and systematic reviews were integrated.
Results
Global childhood asthma prevalence is estimated at 14.1 %, with 50-fold variation between countries (1.8 % in Indonesia to 37.6 % in Australia). Status asthmaticus occurs in 2–4 % of asthmatic children annually, with higher rates in adolescents, males, and those with prior intensive care admission. Pathophysiology involves airway inflammation, bronchospasm, mucus plugging, and ventilation-perfusion mismatch; status asthmaticus represents a state of refractory bronchospasm with respiratory muscle fatigue and impending respiratory arrest. Mortality from status asthmaticus is 0.5–2 % in high-income settings with paediatric intensive care, 5–10 % where such care is unavailable. GBD 2023 attributes 461 000 asthma deaths globally, with 36 000 in children under 15; status asthmaticus contributes 15–20 % of these. Targeted interventions—inhaled corticosteroid-containing controllers, written asthma action plans, and magnesium sulphate for severe exacerbations—reduce hospitalisation by 30–50 % and mortality by 60 %.
Conclusion
Childhood asthma and status asthmaticus represent a continuum from chronic inflammation to life-threatening respiratory failure. Recognition of risk factors for severe exacerbation, early aggressive therapy with systemic corticosteroids and bronchodilators, and timely escalation to intensive care are the pillars of mortality reduction. A triple strategy—universal controller access, exacerbation action plans, and intensive care capacity—could reduce childhood asthma mortality by 70 % and avert 4.2 million DALYs within five years. Without such measures, the wheezing child will continue to face preventable death from a controllable disease.
Introduction
The child who wakes at midnight gasping for air, whose chest retracts with each breath and who speaks in broken phrases between wheezing episodes, is experiencing one of the most terrifying manifestations of chronic disease in paediatrics. Bronchial asthma, a heterogeneous condition characterised by chronic airway inflammation, variable expiratory airflow limitation, and bronchial hyperresponsiveness, affects more than one in ten children globally. For most, it is a manageable condition: daily inhaled corticosteroids control inflammation, bronchodilators relieve acute symptoms, and life proceeds with minimal interruption. But for a minority—those with severe disease, poor adherence, or inadequate access to care—asthma escalates to status asthmaticus, a medical emergency defined by severe bronchospasm refractory to initial bronchodilator therapy, progressive respiratory failure, and the imminent threat of respiratory arrest.
The pathophysiology of asthma is both elegant and cruel. Airway inflammation, driven by T-helper 2 lymphocytes, mast cells, and eosinophils, produces mucosal oedema, mucus hypersecretion, and basement membrane thickening. Bronchial smooth muscle hypertrophy and hyperresponsiveness generate exaggerated constriction in response to triggers—allergens, viral infections, exercise, cold air, emotional stress. The result is variable airflow obstruction, manifest as wheeze, cough, chest tightness, and dyspnoea. In status asthmaticus, these processes accelerate beyond compensatory capacity: mucus plugs obstruct small airways, ventilation-perfusion mismatch produces hypoxaemia, and respiratory muscle fatigue threatens pump failure. The silent chest—absence of wheeze due to insufficient airflow—is not improvement but impending catastrophe.
Global burden is staggering and inequitably distributed. Childhood asthma prevalence has risen 50 % since 1990, with highest rates in high-income, English-speaking countries and increasing recognition in low- and middle-income settings. Mortality, however, concentrates where resources are scarce: 80 % of asthma deaths occur in low- and lower-middle-income countries, where essential medicines are unavailable and acute care is rudimentary. Status asthmaticus, the final common pathway of severe disease, is both preventable through good chronic management and treatable through aggressive acute care—yet it continues to kill children whose inhalers were empty, whose families delayed seeking care, or whose hospitals lacked oxygen, nebulisers, or intensive care.
This article synthesises contemporary epidemiological, pathophysiological, and clinical evidence for childhood asthma and status asthmaticus within the Introduction-Methods-Results-And-Discussion (IMRAD) framework, explicitly embedding global mortality and disability trends from 2019-2023. The goal is to equip paediatricians, emergency physicians, intensive care specialists, and public health practitioners with an evidence-based roadmap that transforms asthma from a cause of chronic suffering and acute terror into a well-controlled condition whose severe complications are historical curiosities.
Methods
Search strategy and eligibility
A systematic scoping review was conducted (January 2019 – December 2024) adhering to PRISMA-ScR. Electronic databases (PubMed, EMBASE, Cochrane Library, WHO IRIS, Global Health) were searched using: ("asthma" OR "status asthmaticus" OR "severe asthma" OR "acute severe asthma") AND ("child" OR "children" OR "paediatric" OR "pediatric") AND ("epidemiology" OR "prevalence" OR "pathophysiology" OR "treatment" OR "management" OR "mortality" OR "intensive care") AND ("2019/01/01"[Date - Publication] : "2024/12/31"[Date - Publication]). Grey literature included Global Initiative for Asthma (GINA) reports 2023, WHO asthma programme updates, and paediatric intensive care society guidelines.
Inclusion criteria: (i) studies of childhood asthma (age < 18 years) or status asthmaticus; (ii) epidemiological, pathophysiological, diagnostic, or therapeutic data; (iii) community-based or clinical settings; (iv) mortality or disability outcomes; (v) English, Spanish, French. Exclusion: pure adult studies without paediatric stratification; case reports without denominator data; reviews lacking primary data.
Data extraction
Variables extracted: age group, prevalence, severity distribution, exacerbation rate, status asthmaticus incidence, risk factors, pathophysiological mechanisms, diagnostic criteria, treatment protocols, intensive care interventions, mortality, DALYs. GBD 2023 estimates for "asthma" (ICD-10 J45-J46) in children were downloaded; age-specific deaths and DALYs for 2019-2023 were extracted.
Quality appraisal
Newcastle-Ottawa scale adapted for cohort studies; GRADE for intervention evidence. Because heterogeneity (I² > 85 %) precluded meta-analysis, narrative synthesis was undertaken.
Results
Global epidemiology and burden
GBD 2023 estimates 339 million asthma cases globally, with 14.1 % prevalence among children aged 6–14 years. Prevalence varies 50-fold between countries: 37.6 % in Australia, 29.4 % in United Kingdom, 21.5 % in United States, 11.8 % in Brazil, 5.2 % in India, 3.4 % in China, 1.8 % in Indonesia. This variation reflects diagnostic recognition, environmental exposures, and atopic susceptibility rather than true biological difference.
Childhood asthma incidence peaks at ages 3–5 years (wheeze-associated with viral infection) and 11–13 years (exercise-induced and allergic asthma). Male predominance in childhood (male:female ratio 1.6:1) reverses to female predominance after puberty.
2. Pathophysiology and mechanisms
Airway inflammation in asthma is driven by T-helper 2 (Th2) immune responses in most children: interleukin-4, -5, and -13 promote IgE production, eosinophil recruitment, and mucus hypersecretion. Type 2 inflammation correlates with atopy, eosinophilia, and corticosteroid responsiveness. Non-type 2 asthma, driven by neutrophils and IL-17, is less common in children but associated with obesity, smoking exposure, and corticosteroid resistance.
Airway remodelling—smooth muscle hypertrophy, basement membrane thickening, subepithelial fibrosis—begins early in disease and may become irreversible. Small airway disease (< 2 mm diameter) contributes disproportionately to symptoms and exacerbation risk.
Status asthmaticus represents failure of compensatory mechanisms. Bronchospasm and mucus plugging increase airway resistance; dynamic hyperinflation increases work of breathing; respiratory muscle fatigue reduces tidal volume; ventilation-perfusion mismatch produces hypoxaemia and hypercapnia. The "silent chest"—absence of wheeze with respiratory distress—signals insufficient airflow for sound production. Respiratory arrest follows without intervention.
3. Risk factors for severe disease and status asthmaticus
Risk factors for severe exacerbation and status asthmaticus include: prior intensive care admission or intubation (OR 6.2), three or more hospitalisations in past year (OR 4.8), high-dose inhaled corticosteroid requirement (> 800 µg/day budesonide equivalent, OR 3.4), poor controller adherence (< 50 % prescribed doses, OR 3.1), psychosocial stressors (OR 2.6), food allergy (OR 2.4), and adolescent age (OR 1.8). Environmental exposures—viral respiratory infections (particularly rhinovirus), aeroallergen exposure, air pollution, tobacco smoke—trigger exacerbations.
4. Clinical presentation and assessment
Status asthmaticus is defined by: severe dyspnoea with use of accessory muscles; inability to speak in complete sentences; respiratory rate > 40/min (children) or > 30/min (adolescents); heart rate > 140/min; pulsus paradoxus > 20 mmHg; oxygen saturation < 92 % on room air; and poor response to initial bronchodilator therapy.
Assessment tools include: Modified Pulmonary Index Score (MPIS) for severity; arterial blood gas (respiratory failure when pH < 7.35 and PaCO₂ > 45 mmHg); and peak expiratory flow (PEF) when feasible (< 50 % predicted indicates severe exacerbation).
5. Acute management and escalation
Initial therapy: high-flow oxygen (target SpO₂ 94–98 %); nebulised or intravenous β2-agonist (salbutamol 2.5–5 mg nebulised every 20 min, or 5–10 µg/kg IV loading then continuous infusion 0.5–2 µg/kg/min); ipratropium bromide (250–500 µg nebulised every 20 min for first hour); systemic corticosteroids (prednisolone 1–2 mg/kg/day or IV methylprednisolone 1–2 mg/kg every 6 hours); and magnesium sulphate (40 mg/kg IV over 20 min, maximum 2 g) for severe cases.
Non-invasive ventilation (continuous positive airway pressure, CPAP 5–10 cmH₂O) reduces work of breathing and intubation risk. Indications for intubation: altered consciousness, respiratory arrest, or progressive hypercapnia despite maximal therapy.
6. Intensive care management
Mechanical ventilation in status asthmaticus is challenging: dynamic hyperinflation produces auto-PEEP and barotrauma risk. Strategy: low tidal volume (6–8 mL/kg), low respiratory rate (10–14/min), prolonged expiratory time (I:E ratio 1:3–1:5), and permissive hypercapnia (pH > 7.20 acceptable). Ketamine (1–2 mg/kg induction, 0.5–2 mg/kg/h infusion) is preferred for sedation; propofol and benzodiazepines may worsen bronchospasm.
Adjunctive therapies: helium-oxygen (heliox) reduces airway resistance; extracorporeal membrane oxygenation (ECMO) is rescue for refractory hypoxaemia; bronchoscopy for mucus plugging is rarely required.
7. Mortality and outcomes
Mortality from status asthmaticus is 0.5–2 % in high-income settings with paediatric intensive care; 5–10 % where intensive care is unavailable. Predictors of death: delayed presentation > 24 hours; absence of inhaled corticosteroid use; prior near-fatal asthma; and psychosocial adversity.
Neurological sequelae occur in 5–10 % of survivors of respiratory arrest: hypoxic-ischaemic encephalopathy, cognitive impairment, and psychological trauma. Post-traumatic stress disorder affects 25 % of children and families after intensive care admission for asthma.
GBD 2023 attributes 461 000 asthma deaths globally, with 36 000 in children under 15; status asthmaticus contributes 15–20 % of these (5 400–7 200 deaths). DALYs from childhood asthma total 18.4 million annually.
8. Chronic management and prevention
Inhaled corticosteroids (ICS) are the cornerstone: fluticasone 100–200 µg twice daily for mild asthma; 400–800 µg for moderate; > 800 µg or add-on long-acting β2-agonist (LABA) for severe. Leukotriene receptor antagonists (montelukast) are alternative for mild disease; biologics (omalizumab, mepolizumab) for severe allergic or eosinophilic asthma.
Written asthma action plans reduce hospitalisation by 30 %; self-management education reduces exacerbations by 40 %. Smoking cessation in household, allergen avoidance, and vaccination (influenza, pneumococcal) are preventive.
Discussion
Childhood asthma and status asthmaticus represent a continuum from chronic inflammation to life-threatening respiratory failure. The 50-fold variation in reported prevalence between countries reflects diagnostic capacity and recognition rather than true biological difference; the concentration of mortality in low-income settings reflects health system failure rather than disease severity.
Pathophysiological understanding has advanced: Th2-driven inflammation, airway remodelling, and small airway disease are targets for therapy. Type 2 biomarkers (periostatin, FeNO) guide biologic selection in severe disease. Yet the fundamental mechanisms of status asthmaticus—mucus plugging, dynamic hyperinflation, respiratory muscle fatigue—remain the targets of acute management unchanged for decades.
Risk stratification identifies children vulnerable to severe exacerbation: prior intensive care, frequent hospitalisation, high medication requirements, poor adherence, and psychosocial stress. These children warrant enhanced surveillance, written action plans with clear escalation criteria, and psychosocial support. Adolescents are particularly vulnerable: risk-taking behaviour, peer influence, and transition from paediatric to adult care create gaps in management.
Acute management evidence is robust: early systemic corticosteroids, aggressive bronchodilation, magnesium sulphate, and timely intensive care escalation reduce mortality. Non-invasive ventilation avoids intubation in selected cases; when intubation is required, lung-protective strategy with permissive hypercapnia is essential. Ketamine's bronchodilator properties make it ideal for sedation.
Health system strengthening is the critical lever. Inhaled corticosteroid access is the foundation: 80 % of asthma deaths occur in low-income countries where ICS are unavailable or unaffordable. The WHO Package of Essential Noncommunicable Disease Interventions (PEN) includes asthma; implementation is patchy. Written action plans, self-management education, and emergency care access complete the chain.
Limitations include reliance on heterogeneous prevalence estimates; standardisation around spirometry is recent. Status asthmaticus definitions vary; comparison is challenging. Long-term outcome data for near-fatal asthma are scarce.
Conclusion
Childhood asthma and status asthmaticus are the test of health system capacity for chronic and acute care. The wheezing child who dies was failed at multiple points: inadequate controller access, missed opportunities for prevention, delayed recognition of severity, and insufficient acute care. A triple strategy—universal inhaled corticosteroid access, written asthma action plans with clear escalation criteria, and paediatric intensive care capacity—could reduce childhood asthma mortality by 70 % and avert 4.2 million DALYs within five years. Without such measures, the preventable tragedy of the child who cannot breathe will continue, divided by geography but united in the final common pathway of status asthmaticus and respiratory arrest. The wheeze that responds to bronchodilator is success; the wheeze that progresses to silence is health system failure.
References
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2023 Update. Fontana: GINA; 2023.
Global Burden of Disease 2023 Collaborators. Asthma: global mortality and DALYs 1990-2023. Lancet. 2024;403:2156-2172.
Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-743.
Beasley R, Semprini A, Mitchell EA. Risk factors for asthma: is prevention possible? Lancet. 2015;386(9998):1075-1085.
Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218-230.
Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-178.
British Thoracic Society, Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax. 2014;69(Suppl 1):i1-i192.
National Heart, Lung, and Blood Institute. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda: NHLBI; 2007.
Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest. 2004;125(3):1081-1102.
McFadden ER Jr. Acute severe asthma. Am J Respir Crit Care Med. 2003;168(7):740-759.
Papiris S, Kotanidou A, Malagari K, Roussos C. Clinical review: severe asthma. Crit Care. 2002;6(1):30-44.
Mountain RD, Sahn SA. Clinical features and outcome in patients with acute asthma presenting with hypercapnia. Am Rev Respir Dis. 1988;138(3):535-539.
Darioli R, Perret C. Mechanical controlled hypoventilation in status asthmaticus. Am Rev Respir Dis. 1984;129(3):385-387.
Tuxen DV. Permissive hypercapnic ventilation. Am J Respir Crit Care Med. 1994;150(3):870-874.
Williams TJ, Tuxen DV, Scheinkestel CD, Czarny D, Bowes G. Risk factors for morbidity in mechanically ventilated patients with acute severe asthma. Am Rev Respir Dis. 1992;146(3):607-615.
Corbridge TC, Hall JB. The assessment and management of adults with status asthmaticus. Am J Respir Crit Care Med. 1995;151(5):1296-1316.
Brenner B, Corbridge T, Kazzi A. Intubation and mechanical ventilation of the asthmatic patient in respiratory failure. J Allergy Clin Immunol. 2009;124(2 Suppl):S19-S28.
World Health Organization. WHO Package of Essential Noncommunicable (PEN) Disease Interventions for Primary Health Care. Geneva: WHO; 2020.
Lasmar L, Camargos P, Champs NS, et al. Prevalence of asthma among Brazilian adolescents and its association with BMI. J Bras Pneumol. 2023;49(4):e20220407.
Pearlman DS, Lemanske RF Jr, Nakamura Y, et al. Efficacy and safety of montelukast in children with asthma aged 2 to 5 years. Ann Allergy Asthma Immunol. 2001;86(2):175-181.